Glucagon-like peptide 1 improves the ability of the β-cell to sense and respond to glucose in subjects with impaired glucose tolerance

Diabetes

Volumn 47, Issue 8, 1998, Pages 1259-1265

  Byrne, Maria M ^a   Gliem, Katja ^a   Wank, Uwe ^a   Arnold, Rudolf ^a   Katschinski, Martin ^a   Polonsky, Kenneth S ^b   Göke, Burkhard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

AREA UNDER THE CURVE; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE INTOLERANCE; HUMANS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0031820844     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.8.1259     Document Type: Article

References (46)

1. Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 years. Diabetes 36:523-534, 1987
2. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Conner EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Haniman RF: Predictors of progression from impaired glucose tolerance to NIDDM. Diabetes 46:701-710, 1997
3. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
4. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L: Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337-343, 1989
5. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med 319:1297-1301, 1988
6. Osei K, Cotrell DA, Orabella MM: Insulin sensitivity, glucose effectiveness and body fat distribution pattern in nondiabetic offspring of patients with NIDDM. Diabetes Care 14:890-896, 1991
7. O'Rahilly S, Turner RC, Matthews DR: Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 318:1225-1230, 1988
8. O'Meara NM, Sturis J, Van Cauter E, Polonsky KS: Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest 92:262-271, 1993
9. Byrne MM, Sturis J, Sobel RJ, Polonsky KS: Elevated plasma glucose 2-hour post challenge predicts defects in beta-cell function. Am J Physiol 270:E572-E579, 1996
10. Rudenski AS, Hadden DR, Atkinson AB, Kennedy L, Matthews DR, Merrett JD, Pockaj B, Turner RC: Natural history of pancreatic islet B-cell function in type II diabetes mellitus studied over six years by homeostasis model assessment. Diabet Med 5:36-41, 1988
11. Hoist JJ, Ørskov C, Vagn Nielsen O, Schwartz TW: Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174, 1987
12. Mojsov S, Weir GC, Habener JF: Insulinotropin: glucagon-like peptide 1 (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79:616-619, 1987
13. Weir GC, Mojsov S, Hendrick GK, Habener JF: Glucagon-like peptide I (7-37) actions on endocrine pancreas. Diabetes 38:338-342, 1989
14. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
15. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendric S: Antidiabetogenic effects of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
16. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in type II (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
17. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044, 1994
18. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530, 1996
19. Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211, 1997
20. Todd JF, Wilding JPH, Edwards CMB, Khan FA, Ghatei MA, Bloom SR: Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536, 1997
21. Sturis J, Van Cauter E, Blackman JD, Polonsky KS: Entrainment of pulsatile insulin secretion by oscillatory glucose infusion. J Clin Invest 87:439-445, 1991
22. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
23. Faber OK, Binder C, Markussen J, Heding LG, Naithani VK, Kuzuya H, Blix P, Horwitz DL, Rubenstein AH: Characterization of seven C-peptide antisera. Diabetes 27 (Suppl. 1):170-177, 1978
24. Herrmann C, Göke R, Richter G, Fehmann H-C, Arnold R, Göke B: Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56:117-126, 1995
25. Van Cauter E, Mestrez F, Sturis J, Polonsky KS: Estimation of insulin secretion rates from C-peptide levels: comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41:368-377, 1992
26. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J: Prehepatic insulin production in man: peripheral analysis using connecting peptide behavior. J Clin Endocrinol Metab 51:520-528, 1980
27. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J, Karrison T, Frank B: Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 77: 98-105, 1986
28. Jenkins GM, Watts DG: Spectral Analysis and Its Applications. San Francisco, CA, Holden Day, 1968
29. Sturis J, Scheen AJ, Leproult R, Polonsky KS, Van Cauter E: 24-hour glucose profiles during continuous or oscillatory insulin infusion: demonstration of the functional significance of ultradian insulin oscillations. J Clin Invest 95:1464-1471, 1995
30. Holz GG, Kühtreiber WM, Habener JF: Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361:362-365, 1993
31. Broderick CL, Heisserman JA, Smiley DL, Miller AR: Effect of sub-chronic administration of GLPI (7-37) OH on beta cell failure in Zucker diabetic rats (Abstract). Diabetologia 38 (Suppl 1):A171, 1995
32. 2+-signaung pathway in pancreatic β-cells by the insulinotropic hormone gtucagon-like peptide-1. J Biol Chem 270:17749-17757, 1995
33. Ämmälä C, Ashcroft FM, Rorsman P: Calcium-independent potentiation of insulin release by cyclic AMP in single β-cells. Nature 363:356-358, 1993
34. Drucker DJ, Phillippe J, Mojsov S, Chick WL, Habener JF: Glucagon-like peptide 1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84:3434-3438, 1987
35. Fehmann H-C, Habener JF: Insulinotropic hormone glucagon-like peptide-1 (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinology 130:159-166, 1992
36. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh C, Elahi D, Egan JM: Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 99:2883-2889, 1997
37. Otonkoski T, Hayek A: Constitution of a biphasic insulin response to glucose in human fetal pancreatic beta-cells with glucagon-like peptide 1. J Clin Endocrinol Metab 80:3779-3783, 1995
38. Rosetti L, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 13:610-629, 1990
39. Flax H, Matthews DR, Levy JC, Coppack SW, Turner RC: No glucotoxicity after 53 h of 6.0 mmol/1 hyperglycemia in normal man. Diabetologia 34:570-575, 1991
40. Leahy JL, Bonner-Weir S, Weir GC: β-cell dysfunction induced by chronic hyperglycemia. Diabetes Care 15:442-455, 1992
41. Leahy JL, Cooper HE, Deal DA, Weir GC: Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. J Clin Invest 77:908-915, 1986
42. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW: Glucagon-like peptide-1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266, 1994
43. D'Alessio DA, Pridgeon RL, Ensinck JW: Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes: a physiological role of glucagon-like peptide 1. Diabetes 44:1433-1437, 1995
44. Orskov L, Holst JJ, Moller J, Orskov C, Moller N, Alberti KGMM, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232, 1996
45. Ahren B, Larsson H, Holst JJ: Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478, 1997
46. Toft-Nielsen M, Madsbad S, Holst JJ: The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556, 1996